The DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index; none of the 73 sources its claims cite is checked for support yet.
Basic mechanisms of high‐risk human papillomavirus‐induced carcinogenesis: Roles of E6 and E7 proteins
Open accessAbstract
Human papillomaviruses (HPV) are believed to be the primary causal agents for development of pre‐neoplastic and malignant lesions of the uterine cervix, and high‐risk types such as type 16 and 18 are associated with more than 90% of all cervical carcinomas. The E6 and E7 genes of HPV are thought to play causative roles, since E6 promotes the degradation of p53 through its interaction with E6AP, an E3 ubiquitin ligase, whereas E7 binds to the retinoblastoma protein (pRb) and disrupts its complex formation with E2F transcription factors. Although prophylactic vaccines have become available, it is still necessary to clarify the mechanisms of HPV‐induced carcinogenesis because of the widespread nature of HPV infection. Approximately 493 000 new cases of cervical cancer are diagnosed each year with approximately 274 000 mortalities due to invasive cervical cancer. In the present article, the mechanisms of HPV16 E6‐ and E7‐induced multistep carcinogenesis and recently identified functions of these onco‐proteins are reviewed. (Cancer Sci 2007; 98: 1505–1511)
Overview
CoChat Summary
Written by AI from the paper’s full text.
TL;DR
This review summarizes how high-risk HPV E6 and E7 oncoproteins drive cervical carcinogenesis by inactivating p53 and pRb family proteins and by targeting additional cellular pathways. It emphasizes that overexpression of E6/E7, usually after viral integration, is a bottleneck step that cooperates with further genetic and epigenetic changes.
Key findings
- High-risk HPV types (16, 18, 31, 33, 45, 51, 52, 58, etc.) are associated with more than 90% of cervical cancers; HPV16 accounts for approximately half and HPV18 for another 10–20%. Approximately 493,000 new cervical cancer cases and 274,000 deaths occur annually.
- E6 promotes degradation of p53 through interaction with E6AP, an E3 ubiquitin ligase, while E7 binds pRb family proteins and disrupts pRb–E2F complexes; together they cause polyploidy and genomic instability.
- E6 has p53-independent functions, including hTERT/telomerase induction and degradation of PDZ-domain proteins such as DLG, Scribble, MUPP1, MAGI-1/-2/-3, GIPC, PATJ, PTPN3, and PSD95; E7 targets many proteins including p27, p21, p600, and PP2A.
- Integration and high-level E6/E7 expression are proposed as the bottleneck step; additional events reported in cervical cancers include PIK3CA, c-myc, ErbB2, and cIAP1 amplification, ras mutation, and decreased PTEN and TSLC1 expression.
Methods
- Narrative review; no primary experimental data, sample, or systematic analysis are reported.
- Synthesizes published literature and the authors’ recent work on HPV16 E6- and E7-induced multistep carcinogenesis, the HPV life cycle, and target proteins of E6 and E7 (Table 1; Figs 1–5).
Limitations
- The paper does not state formal limitations; it notes that further exploration is needed for TSC2/Tuberin as a possible E6 target.
- Evident from the text: this is a narrative review without stated systematic search or inclusion criteria, and some mechanistic claims rely on cited reviews, speculation, or a personal communication (A. Suhrbier, 2007) regarding E7-mediated pRb cleavage.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
57 Sources not found · 14 Own interpretation
In the paper
“The most manifest function of the E6 protein is to promote the degradation of p53 through its interaction with a cellular protein, E6 associated protein (E6AP), an E3 ubiquitin ligase (9)”
§ Basic mechanisms of high-risk human papillomavirusinduced carcinogenesis: Roles of E6 and E7 proteins > The functions of HPV onco-proteins E6 and E7
What the sources say
- Not matchedcites [9]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
In the paper
“in the presence of E6, a repressor complex of TERT promoter, containing USF1 and USF2, is replaced by Myc, which corresponds to higher levels of TERT transcription and consequently, telomerase activity.(35)”
§ Basic mechanisms of high-risk human papillomavirusinduced carcinogenesis: Roles of E6 and E7 proteins > The functions of HPV onco-proteins E6 and E7
What the sources say
- Not matchedcites [35]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
In the paper
“The interaction of E7 with cyclin-dependent kinase (CDK)2/cyclin A, (60) as well as CDK2/cyclin E, (61) has also been reported.”
§ Basic mechanisms of high-risk human papillomavirusinduced carcinogenesis: Roles of E6 and E7 proteins > IRF1
What the sources say
- Not matchedcites [60]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
In the paper
“For evasion of the immune system, E7 also interacts with p48, (64) as well as IRF1.(8)”
§ Basic mechanisms of high-risk human papillomavirusinduced carcinogenesis: Roles of E6 and E7 proteins > IRF1
What the sources say
- Not matchedcites [64]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
In the paper
“E6 and Myc interaction has been shown to activate the telomerase reverse transcriptase promoter, (34)”
§ Basic mechanisms of high-risk human papillomavirusinduced carcinogenesis: Roles of E6 and E7 proteins > The functions of HPV onco-proteins E6 and E7
What the sources say
- Not matchedcites [34]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
- Probably not a substantial claim. 9
- It may state two separate claims as one. 18
Create a free account to see these claims.
Create a free account to see these assumptions.
42 more claims
Create a free account to see all 71 claims and every source verdict.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Basic mechanisms of high-risk human papillomavirusinduced carcinogenesis: Roles of E6 and E7 proteins > Tyk2
“TSC2 (tubulin)”
§ Basic mechanisms of high-risk human papillomavirusinduced carcinogenesis: Roles of E6 and E7 proteins > The functions of HPV onco-proteins E6 and E7
“The tumor suppressor gene TSC2 product, Tuberin”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Basic mechanisms of high-risk human papillomavirusinduced carcinogenesis: Roles of E6 and E7 proteins > HPV infection and HPV-induced transformation
“The ultimate development of cervical cancer is rarely accompanied by high expression of E6 and E7 proteins.”
§ Basic mechanisms of high-risk human papillomavirusinduced carcinogenesis: Roles of E6 and E7 proteins > HPV infection and HPV-induced transformation
“CIN III (severe dysplasia, carcinoma in situ) and invasive cancer lesions often display high-level expression of E6 and E7”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Basic mechanisms of high-risk human papillomavirusinduced carcinogenesis: Roles of E6 and E7 proteins > The functions of HPV onco-proteins E6 and E7
“Therefore, its down regulation through p53 with E6/E6AP has been revealed as a novel tumor suppressor mechanism blocking development of HPV-induced cervical carcinogenesis.”
§ Basic mechanisms of high-risk human papillomavirusinduced carcinogenesis: Roles of E6 and E7 proteins > The functions of HPV onco-proteins E6 and E7
“its down-regulation by E6 might contribute to the development of cervical cancer.”
Citations
Cites
Epidemiologic classification of human papillomavirus types associated with cervical cancer
Muñoz, N., Bosch, F. X., de Sanjosé, S., Herrero, R., Castellsagué, X., Shah, K. V., Snijders, P. J. F., & Meijer, C. J. L. M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021641 · Cited by 6,249
Papillomaviruses and cancer: from basic studies to clinical application
Hausen, H. Z. (2002) · Nature reviews. Cancer · doi:10.1038/nrc798 · Cited by 4,094
The regulation of E2F by pRB-family proteins.
Dyson, N. (1998) · Genes & Development · doi:10.1101/gad.12.15.2245 · Cited by 2,317
Ellisen, L. W., Bird, J., West, D. C., Soreng, A. L., Reynolds, T. C., Smith, S. D., & Sklar, J. (1991) · Cell · doi:10.1016/0092-8674(91)90111-b · Cited by 1,691
Role of a p53 polymorphism in the development of human papilloma-virus-associated cancer
Storey, A., Thomas, M., Kalita, A., Harwood, C. A., Gardiol, D., Mantovani, F., Breuer, J., Leigh, I. M., Matlashewski, G., & Banks, L. (1998) · Nature · doi:10.1038/30400 · Cited by 971
Notch1 functions as a tumor suppressor in mouse skin
Nicolas, M., Wolfer, A., Raj, K., Kummer, J. A., Mill, P., van Noort, M., Hui, C., Clevers, H. C., Dotto, G. P., & Radtke, F. (2003) · Nature Genetics · doi:10.1038/ng1099 · Cited by 969
Notch signaling is a direct determinant of keratinocyte growth arrest and entry into differentiation
Rangarajan, A., Talora, C., Okuyama, R., Nicolas, M., Mammucari, C., Oh, H., Aster, J. C., Krishna, S., METZGER, D., Chambon, P., et al. (2001) · The EMBO Journal · doi:10.1093/emboj/20.13.3427 · Cited by 867
The Ets family of transcription factors
Wasylyk, B., Hahn, S. L., & Giovane, A. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb19864.x · Cited by 839
Mechanisms of human papillomavirus-induced oncogenesis
Münger, K., Baldwin, A., Edwards, K. M., Hayakawa, H., Nguyen, C. L., Owens, M., Grace, M., & Huh, K. (2004) · Journal of Virology · doi:10.1128/jvi.78.21.11451-11460.2004 · Cited by 815
Telomerase activation by the E6 gene product of human papillomavirus type 16
Klingelhutz, A. J., Foster, S. A., & McDougall, J. K. (1996) · Nature · doi:10.1038/380079a0 · Cited by 660
Ronco, L. V., Karpova, A. Y., Vidal, M., & Howley, P. M. (1998) · Genes & Development · doi:10.1101/gad.12.13.2061 · Cited by 544
Kiyono, T., Hiraiwa, A., Fujita, M., Hayashi, Y., Akiyama, T., & Ishibashi, M. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.21.11612 · Cited by 428
Self-citationFunk, J. O., Waga, S., Harry, J. B., Espling, E., Stillman, B., & Galloway, D. A. (1997) · Genes & Development · doi:10.1101/gad.11.16.2090 · Cited by 419
Klaes, R., Woerner, S. M., Ridder, R., Wentzensen, N., Duerst, M., Schneider, A., Lotz, B., Melsheimer, P., & Doeberitz, M. V. K. (1999) · PubMed · Cited by 406
Epidermal stem cells: markers, patterning and the control of stem cell fate
Watt, F. M. (1998) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.1998.0247 · Cited by 403
Nakagawa, S., & Huibregtse, J. M. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.21.8244-8253.2000 · Cited by 382
Lee, S. S., Weiss, R. S., & Javier, R. T. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.13.6670 · Cited by 356
Alterations in Notch signaling in neoplastic lesions of the human cervix.
Zagouras, P., Stifani, S., Blaumueller, C. M., Carcangiu, M. L., & Artavanis‐Tsakonas, S. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.14.6414 · Cited by 352
Inactivation of the cdk inhibitor p27KIP1 by the human papillomavirus type 16 E7 oncoprotein.
Zerfass, K., Zwerschke, W., Mannhardt, B., Tindle, R. W., Botz, J. W., & Jansen‐Dürr, P. (1996) · PubMed · Cited by 333
Doeberitz, M. V. K. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00462-8 · Cited by 332
Lefort, K., Mandinova, A., Ostano, P., Kolev, V. N., Calpini, V., Kolfschoten, I., Devgan, V., Lieb, J., Raffoul, W., Hohl, D., et al. (2007) · Genes & Development · doi:10.1101/gad.1484707 · Cited by 313
Zimmermann, H., Degenkolbe, R., Bernard, H.-U., & O’Connor, M. J. (1999) · Journal of Virology · doi:10.1128/jvi.73.8.6209-6219.1999 · Cited by 282
Gewin, L., Myers, H., Kiyono, T., & Galloway, D. A. (2004) · Genes & Development · doi:10.1101/gad.1214704 · Cited by 277
Self-citationLee, S. S., Glaunsinger, B. A., Mantovani, F., Banks, L., & Javier, R. T. (2000) · Journal of Virology · doi:10.1128/jvi.74.20.9680-9693.2000 · Cited by 273
The E7 oncoprotein associates with Mi2 and histone deacetylase activity to promote cell growth
Brehm, A., Nielsen, S. J., Miska, E. A., McCance, D. J., Reid, J. L., Bannister, A. J., & Kouzarides, T. (1999) · The EMBO Journal · doi:10.1093/emboj/18.9.2449 · Cited by 267
Glaunsinger, B. A., Lee, S. S., Thomas, M., Banks, L., & Javier, R. (2000) · Oncogene · doi:10.1038/sj.onc.1203906 · Cited by 264
Li, S., Labrecque, S., Gauzzi, M. C., Cuddihy, A. R., Wong, A. H., Pellegrini, S., Matlashewski, G. J., & Koromilas, A. E. (1999) · Oncogene · doi:10.1038/sj.onc.1202960 · Cited by 245
Liu, X., Clements, A. M., Zhao, K., & Marmorstein, R. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m508455200 · Cited by 243
The Human Papillomavirus E7 Oncoprotein Abrogates Signaling Mediated by Interferon-α
Barnard, P., & McMillan, N. A. J. (1999) · Virology · doi:10.1006/viro.1999.9771 · Cited by 235
Nguyen, M. L., Nguyen, M. M., Lee, D., Griep, A. E., & Lambert, P. F. (2003) · Journal of Virology · doi:10.1128/jvi.77.12.6957-6964.2003 · Cited by 230
Modulation of type M 2 pyruvate kinase activity by the human papillomavirus type 16 E7 oncoprotein
Zwerschke, W., Mazurek, S., Massimi, P., Banks, L., Eigenbrodt, E., & Jansen-Dürr, P. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.4.1291 · Cited by 223
Veldman, T., Liu, X., Yuan, H., & Schlegel, R. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1435900100 · Cited by 214
Talora, C., Sgroi, D. C., Crum, C. P., & Dotto, G. P. (2002) · Genes & Development · doi:10.1101/gad.988902 · Cited by 206
TSLC1 Gene Silencing in Cervical Cancer Cell Lines and Cervical Neoplasia
Steenbergen, R. D. M., Kramer, D., Braakhuis, B. J. M., Stern, P. L., Verheijen, R. H. M., Meijer, C. J. L. M., & Snijders, P. J. F. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh031 · Cited by 204
Regulation of Notch1 Gene Expression by p53 in Epithelial Cells
Yugawa, T., Handa, K., Narisawa‐Saito, M., Ohno, S.-I., Fujita, M., & Kiyono, T. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.02119-06 · Cited by 199
Self-citationThe APC-hDLG complex negatively regulates cell cycle progression from the G0/G1 to S phase
Ishidate, T., Matsumine, A., Toyoshima, K., & Akiyama, T. (2000) · Oncogene · doi:10.1038/sj.onc.1203309 · Cited by 186
Huh, K.-W., DeMasi, J., Ogawa, H., Nakatani, Y., Howley, P. M., & Münger, K. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0505337102 · Cited by 176
Thomas, M., & Banks, L. (1999) · Journal of General Virology · doi:10.1099/0022-1317-80-6-1513 · Cited by 166
Antinore, M. J., Birrer, M. J., Patel, D., Nader, L., & McCance, D. J. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00546.x · Cited by 165
Longworth, M. S., & Laimins, L. A. (2004) · Journal of Virology · doi:10.1128/jvi.78.7.3533-3541.2004 · Cited by 163
HPV-mediated transformation of the anogenital tract
Steenbergen, R. D. M., de Wilde, J., Wilting, S. M., Brink, A. A. T. P., Snijders, P. J. F., & Meijer, C. J. L. M. (2005) · Journal of Clinical Virology · doi:10.1016/j.jcv.2004.11.019 · Cited by 159
Shai, A., Brake, T., Somoza, C., & Lambert, P. F. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3344 · Cited by 158
Pim, D., Massimi, P., Dilworth, S. M., & Banks, L. (2005) · Oncogene · doi:10.1038/sj.onc.1208935 · Cited by 156
Imoto, I., Tsuda, H., Hirasawa, A., Miura, M., Sakamoto, M., Hirohashi, S., & Inazawa, J. (2002) · PubMed · Cited by 154
Bertelsen, B. I., Steine, S. J., Sandvei, R., Molven, A., & Lærum, O. D. (2005) · International Journal of Cancer · doi:10.1002/ijc.21461 · Cited by 153
Berezutskaya, E., & Bagchi, S. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.48.30135 · Cited by 152
Human Papillomavirus E7 Oncoproteins Bind a Single Form of Cyclin E in a Complex with cdk2 and p107
McIntyre, M., Ruesch, M. N., & Laimins, L. A. (1996) · Virology · doi:10.1006/viro.1996.0008 · Cited by 151
McMurray, H. R., & McCance, D. J. (2003) · Journal of Virology · doi:10.1128/jvi.77.18.9852-9861.2003 · Cited by 143
Human papillomavirus in a necessary cause of invasive cervical cancer worldwide
(1999) · Pure Amsterdam UMC · doi:10.1002/(sici)1096-9896(199909)189:1 · Cited by 140
α6 Integrin Is the Main Receptor of Human Papillomavirus Type 16 VLP
Yoon, C., Kim, K.-D., Park, S.-N., & Cheong, S. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.4838 · Cited by 133
Watson, R. A., Thomas, M., Banks, L., & Roberts, S. (2003) · Journal of Cell Science · doi:10.1242/jcs.00809 · Cited by 129
Abrogation of IRF-1 response by high-risk HPV E7 protein in vivo
Um, S., Rhyu, J.-W., Kim, E.-J., Jeon, K.-C., Hwang, E.-S., & Park, J. S. (2002) · Cancer Letters · doi:10.1016/s0304-3835(01)00871-0 · Cited by 126
Proteomic Analysis of β1-Adrenergic Receptor Interactions with PDZ Scaffold Proteins
He, J., Bellini, M., Inuzuka, H., Xu, J., Xiong, Y., Yang, X., Castleberry, A. M., & Hall, R. A. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m509503200 · Cited by 126
Massimi, P., Gammoh, N., Thomas, M., & Banks, L. (2004) · Oncogene · doi:10.1038/sj.onc.1207977 · Cited by 124
Human papillomavirus and disease mechanisms: relevance to oral and cervical cancers*
Nair, S. A., & Pillai, M. (2005) · Oral Diseases · doi:10.1111/j.1601-0825.2005.01127.x · Cited by 122
Garnett, T. O., Filippova, M., & Duerksen-Hughes, P. J. (2006) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401886 · Cited by 122
Arroyo, M., Bagchi, S., & Raychaudhuri, P. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.10.6537 · Cited by 119
Gu, W., Tom, L. N., Hengst, K., Minto, K., Saunders, N. A., Leggatt, G. R., & McMillan, N. A. J. (2006) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700971 · Cited by 119
Ming, J., Bohl, J., Brimer, N., Kinter, M. T., & Pol, S. V. (2006) · Journal of Virology · doi:10.1128/jvi.01979-06 · Cited by 112
Lüscher‐Firzlaff, J., WESTENDORF, J. M., Zwicker, J., Burkhardt, H., Arsenian‐Henriksson, M., Müller, R., Pirollet, F., & Lüscher, B. (1999) · Oncogene · doi:10.1038/sj.onc.1202967 · Cited by 110
Zhang, A., Månér, S., Betz, R. C., Ångström, T., Stendahl, U., Bergman, F., Zetterberg, A., & Wallin, K. (2002) · International Journal of Cancer · doi:10.1002/ijc.10627 · Cited by 105
Schilling, B., De-Medina, T., Syken, J., Vidal, M., & Münger, K. (1998) · Virology · doi:10.1006/viro.1998.9220 · Cited by 103
Kazemi, S., Papadopoulou, S., Li, S., Su, Q., Wang, S., Yoshimura, A., Matlashewski, G., Dever, T. E., & Koromilas, A. E. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.8.3415-3429.2004 · Cited by 99
Storrs, C. H., & Silverstein, S. (2007) · Journal of Virology · doi:10.1128/jvi.02545-06 · Cited by 96
Lu, Z., Hu, X., Li, Y., Zheng, L., Zhou, Y., Jiang, H., Ning, T., Basang, Z., Zhang, C., & Ke, Y. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m403385200 · Cited by 96
RB acute loss induces centrosome amplification and aneuploidy in murine primary fibroblasts
Iovino, F., Lentini, L., Amato, A., & Di Leonardo, A. (2006) · Molecular Cancer · doi:10.1186/1476-4598-5-38 · Cited by 94
Ishikawa, M., Fujii, T., Saito, M., Nindl, I., ONO, A., Kubushiro, K., Tsukazaki, K., Mukai, M., & NOZAWA, S. (2006) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2006.00355.x · Cited by 93
BRCA1 Interaction with Human Papillomavirus Oncoproteins
Zhang, Y., Fan, S., Meng, Q., Ma, Y., Katiyar, P., Schlegel, R., & Rosen, E. M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m505124200 · Cited by 93
Patel, D., Incassati, A., Wang, N., & McCance, D. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2917 · Cited by 92
Kukimoto, I., Aihara, S., Yoshiike, K., & Kanda, T. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.9066 · Cited by 82
Incassati, A., Patel, D., & McCance, D. J. (2005) · Oncogene · doi:10.1038/sj.onc.1209276 · Cited by 80
Telomeres and Telomerase: Pharmacological Targets for New Anticancer Strategies?
Pendino, F., Tárkányi, I., Dudognon, C., Hillion, J., Lanotte, M., Aradi, J., & Segal-Bendirdjian, E. (2006) · Current Cancer Drug Targets · doi:10.2174/156800906776056482 · Cited by 80
Katzenellenbogen, R. A., Egelkrout, E. M., Vliet-Gregg, P., Gewin, L. C., Gafken, P. R., & Galloway, D. A. (2007) · Journal of Virology · doi:10.1128/jvi.02007-06 · Cited by 78
Inhibition of Papillomavirus Protein Function in Cervical Cancer Cells by Intrabody Targeting
Griffin, H. M., Elston, R., Jackson, D. J., Ansell, K. H., Coleman, M. M., Winter, G. P., & Doorbar, J. (2005) · Journal of Molecular Biology · doi:10.1016/j.jmb.2005.10.077 · Cited by 76
Favre-Bonvin, A., Reynaud, C., Kretz‐Remy, C., & Jalinot, P. (2005) · Journal of Virology · doi:10.1128/jvi.79.7.4229-4237.2005 · Cited by 76
p600, a unique protein required for membrane morphogenesis and cell survival
Nakatani, Y., Konishi, H., Vassilev, A. P., Kurooka, H., Ishiguro, K., Sawada, J., Ikura, T., Korsmeyer, S. J., Qin, J., & Herlitz, A. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507458102 · Cited by 73
E6AP-Dependent Degradation of DLG4/PSD95 by High-Risk Human Papillomavirus Type 18 E6 Protein
Handa, K., Yugawa, T., Narisawa‐Saito, M., Ohno, S.-I., Fujita, M., & Kiyono, T. (2006) · Journal of Virology · doi:10.1128/jvi.01712-06 · Cited by 73
Self-citationExamination of the pRb-Dependent and pRb-Independent Functions of E7 In Vivo
Balsitis, S. J., Dick, F. A., Lee, D., Farrell, L., Hyde, R. K., Griep, A. E., Dyson, N. J., & Lambert, P. F. (2005) · Journal of Virology · doi:10.1128/jvi.79.17.11392-11402.2005 · Cited by 67
Nagasaka, K., Nakagawa, S., Yano, T., Takizawa, S., Matsumoto, Y., Tsuruga, T., Nakagawa, K., Minaguchi, T., Oda, K., Hiraike‐Wada, O., et al. (2006) · Cancer Science · doi:10.1111/j.1349-7006.2006.00315.x · Cited by 67
Phillips, A. C., & Vousden, K. H. (1997) · Journal of General Virology · doi:10.1099/0022-1317-78-4-905 · Cited by 60
Narisawa‐Saito, M., Handa, K., Yugawa, T., Ohno, S.-I., Fujita, M., & Kiyono, T. (2006) · Oncogene · doi:10.1038/sj.onc.1210118 · Cited by 58
Self-citationKw, J., Kim, H.-Z., Kim, S., Kim, Y.-S., & Choe, J. (2006) · Oncogene · doi:10.1038/sj.onc.1209837 · Cited by 56
Gabius, S., Joshi, S., Gabius, H., & Jg, S. (1991) · PubMed · Cited by 15
Association of PTEN mutation with HPV-negative adenocarcinoma of the uterine cervix
Minaguchi, T., Yoshikawa, H., Nakagawa, S., Yasugi, T., Yano, T., Iwase, H., Mizutani, K., Shiromizu, K., Ohmi, K., Watanabe, Y., et al. (2004) · Cancer Letters · doi:10.1016/j.canlet.2004.03.017 · Cited by 14
Mattiussi, S., MATSUMOTO, K., Illi, B., Martelli, F., Capogrossi, M. C., & Gaetano, C. (2006) · Cardiovascular Research · doi:10.1016/j.cardiores.2006.02.008 · Cited by 9
Cited by
The DNA-damage response in human biology and disease
Jackson, S. P., & Bartek, J. (2009) · Nature · doi:10.1038/nature08467 · Cited by 6,092
The HECT Family of E3 Ubiquitin Ligases: Multiple Players in Cancer Development
Bernassola, F., Karin, M., Ciechanover, A., & Melino, G. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.06.001 · Cited by 541
Human papillomavirus vaccine against cervical cancer: Opportunity and challenge
Wang, R., Pan, W. D., Lei, J., Huang, W., Li, Y., Wu, D., Gao, C., Ma, D., & Liao, S. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.11.039 · Cited by 530
Enhanced Protein Degradation by Branched Ubiquitin Chains
Meyer, H., & Rapé, M. (2014) · Cell · doi:10.1016/j.cell.2014.03.037 · Cited by 500
Papillomavirus E6 oncoproteins
Pol, S. V., & Klingelhutz, A. J. (2013) · Virology · doi:10.1016/j.virol.2013.04.026 · Cited by 374
Metadata
- Authors
- Narisawa‐Saito, M., & Kiyono, T.
- Affiliations
- National Cancer Center Research Institute (JP)
- Corresponding author
- Kiyono, Tohru
- ORCID
- Kiyono, Tohru
- Venue
- Cancer Science
- Publisher
- Wiley
- Published
- 2007-07-23
- Volume
- 98
- Issue
- 10
- Pages
- 1505-1511
- ISSN
- 1347-9032 (ISSN-L)
- 1349-7006
- PMC
- PMC11158331
- OpenAlex
- W2011499737
- Cited by
- 528
- References
- 85
- Citations by year
- 2026: 13 · 2025: 27 · 2024: 46 · 2023: 24 · 2022: 33 · 2021: 43 · 2020: 32 · 2019: 24 · 2018: 36 · 2017: 27 · 2016: 23 · 2015: 25 · 2014: 25 · 2013: 26 · 2012: 27
- FWCI
- 2.56
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cancer Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Cervical Cancer and HPV Research
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Oncology › Viral-associated cancers and disorders
- Keywords
- human papillomavirus, HPV16, HPV 18, cervical cancer, carcinogenesis, E6 oncoprotein, E7 oncoprotein, p53 degradation, UBE3A, retinoblastoma protein, E2F transcription factors, viral oncogenesis, HPV vaccine
- MeSH terms
- Cell Transformation, Neoplastic, Cell Transformation, Viral, Uterine Cervical Neoplasms, Female, Humans, Oncogene Proteins, Viral, Repressor Proteins, Papillomaviridae, Papillomavirus Infections, Papillomavirus E7 Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-12, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-12 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
